William H. Bradley

William H. Bradley

Obstetrics and Gynecology | Oncology

8800 W. Doyne Ave.
Milwaukee, WI 53226

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

TAOK3 inhibition constrains invasion, potentiates paclitaxel, and reprograms the tumor microenvironment toward anti-tumor immunity in cervical cancer.

TAOK3 inhibition constrains invasion, potentiates paclitaxel, and reprograms the tumor microenvironment toward anti-tumor immunity in cervical cancer.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2026

MRPL47 as a Novel Mitochondrial Biomarker for Early Detection and Therapeutic Response in Ovarian Cancer.

MRPL47 as a Novel Mitochondrial Biomarker for Early Detection and Therapeutic Response in Ovarian Cancer.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings.

Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings.

Journal: Expert opinion on investigational drugs

Published: February 26, 2026

Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].

Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].

Journal: Gynecologic oncology

Published: November 07, 2025

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.

Journal: Gynecologic oncology

Published: April 08, 2025

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 29, 2024

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.

Journal: Cancer

Published: November 09, 2023

Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer.

Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer.

Journal: Frontiers in oncology

Published: September 08, 2023

Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies.

Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies.

Journal: Brachytherapy

Published: March 29, 2023

Pathologic, immunologic, and clinical analysis of the microsatellite instability phenotype in endometrial carcinoma.

Pathologic, immunologic, and clinical analysis of the microsatellite instability phenotype in endometrial carcinoma.

Journal: Human pathology

Published: March 09, 2023

Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial.

Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial.

Journal: JCO clinical cancer informatics

Published: January 06, 2023

A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor.

A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor.

Journal: Gynecologic oncology reports

Published: November 11, 2022

Showing 1-12 of 42

Last Updated: 09/26/2026